Carvedilol: Should be taken with food. Take w/ food to reduce orthostatic effects.
|
Patient with decompensated heart failure requiring IV inotropic treatment, bronchial asthma or related bronchospastic conditions, 2nd- or 3rd-degree AV block without permanent pacemaker, severe bradycardia (<50 bpm), sick sinus syndrome, cardiogenic shock, untreated phaeochromocytoma, Severe hepatic impairment.
|
Patient with salt and volume depletion, hypotension; ischaemic heart disease, Prinzmetal's variant angina, diabetes mellitus, thyrotoxicosis, peripheral vascular disease, psoriasis. Avoid abrupt withdrawal. Renal and mild to moderate hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause syncope during initial therapy, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, heart rate, BUN, blood glucose (diabetics), renal and liver function.
|
Significant: Hypotension with or without syncope, bradycardia.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Dyspnoea, pulmonary oedema.
Eye disorders: Visual impairment, eye irritation, dry eye.
Gastrointestinal disorders: Nausea, diarrhoea, vomiting, dyspepsia, abdominal pain.
General disorders and administration site conditions: Asthenia, fatigue.
Infections and infestations: Bronchitis.
Metabolism and nutrition disorders: Oedema, hypervolaemia, weight gain, hypercholesterolaemia, hyperglycaemia, hypoglycaemia.
Musculoskeletal and connective tissue disorders: Pain in extremities, arthralgia.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Depression.
Renal and urinary disorders: Micturition disorders, abnormal renal function, renal failure.
Vascular disorders: Orthostatic hypotension, peripheral vascular disease.
|
C
D in 2nd & 3rd trimesters.
|
Additive effect with Ca channel blockers (e.g. diltiazem, verapamil), amiodarone, MAO inhibitors, reserpine, guanfacine, methyldopa. May increase atrioventricular conduction time and decrease heart rate with digitalis glycosides. Increased serum concentrations of ciclosporin. Increased hypoglycaemic effect of insulin and oral antidiabetics. May cause synergistic, negative inotropic and hypotensive effect with anaesthetics. Serum concentration may be reduced by CYP450 inducers (e.g. rifampicin, barbiturates) or increased by CYP450 inhibitors (e.g. ketoconazole, cimetidine, fluoxetine, haloperidol, erythromycin). Increased vasoconstriction effect with ergotamine.
|
|
|
C07AG02 - carvedilol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases.
|
Sign Out
